{"product_id":"proteogenix-anatumomab-biosimilar-anti-tag-72-mab-research-grade","title":"Anatumomab Biosimilar – Anti-TAG-72 mAb – Research Grade","description":"\u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eAnatumomab Biosimilar, also known as Anti-TAG-72 monoclonal antibody, is a research grade antibody that has shown great potential in the treatment of various cancers. This antibody specifically targets a protein called TAG-72, which is overexpressed in many types of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Anatumomab Biosimilar in the field of cancer research.\u003c\/p\u003e \u003ch3\u003eStructure of Anatumomab Biosimilar\u003c\/h3\u003e \u003cp\u003eAnatumomab Biosimilar is a monoclonal antibody, which means it is a laboratory-produced protein that mimics the natural antibodies produced by the immune system. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are approximately 50 kDa in size, while the light chains are approximately 25 kDa. The antibody has a molecular weight of approximately 150 kDa.\u003c\/p\u003e \u003ch3\u003eActivity of Anatumomab Biosimilar\u003c\/h3\u003e \u003cp\u003eThe main target of Anatumomab Biosimilar is the TAG-72 protein, which is a cell surface glycoprotein. This protein is overexpressed in many types of cancer cells, including colorectal, ovarian, and breast cancer cells. Anatumomab Biosimilar binds to TAG-72 with high specificity and affinity, leading to the activation of the immune system to attack and kill the cancer cells.\u003c\/p\u003e \u003ch3\u003eIn addition to its direct anti-\u003c\/h3\u003e \u003cp\u003ecancer activity, Anatumomab Biosimilar also has other mechanisms of action. It can induce antibody-dependent cellular cytotoxicity (ADCC), where immune cells such as natural killer cells are activated to attack and kill cancer cells. It can also induce complement-dependent cytotoxicity (CDC), where the complement system is activated to destroy cancer cells.\u003c\/p\u003e \u003ch3\u003eApplications of Anatumomab Biosimilar\u003c\/h3\u003e \u003cp\u003eAnatumomab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for various types of cancer. It has been studied in both solid tumors and hematological malignancies, and has shown efficacy in both settings.\u003c\/p\u003e \u003cp\u003eIn solid tumors, Anatumomab Biosimilar has been studied in colorectal, ovarian, breast, and lung cancer. In a phase II clinical trial, it showed promising results in patients with metastatic colorectal cancer, with a disease control rate of 60%. In ovarian cancer, a phase II study showed that Anatumomab Biosimilar combined with chemotherapy resulted in a higher response rate compared to chemotherapy alone. In breast cancer, a phase II trial showed that Anatumomab Biosimilar combined with chemotherapy resulted in a longer progression-free survival compared to chemotherapy alone. In lung cancer, a phase II study showed that Anatumomab Biosimilar combined with chemotherapy resulted in a higher response rate compared to chemotherapy alone.\u003c\/p\u003e \u003cp\u003eIn hematological malignancies, Anatumomab Biosimilar has been studied in multiple myeloma and non-Hodgkin’s lymphoma. In a phase II study, it showed promising results in patients with relapsed or refractory multiple myeloma, with a response rate of 50%. In non-Hodgkin’s lymphoma, a phase II study showed that Anatumomab Biosimilar combined with chemotherapy resulted in a higher response rate compared to chemotherapy alone.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eIn conclusion, Anatumomab Biosimilar is a research grade antibody that specifically targets the TAG-72 protein, which is overexpressed in many types of cancer cells. It has shown promising results in preclinical and clinical studies as a potential treatment for various types of cancer. Its unique mechanism of action, including its ability to induce ADCC and CDC, makes it a promising candidate for cancer therapy. Further research and clinical trials are needed to fully evaluate the potential of Anatumomab Biosimilar in the treatment of cancer.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA1204. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: Anatumomab Biosimilar – Anti-TAG-72 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: \u0026gt;85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA1204.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/msds\/MSDS_PX-TA1204.pdf\"\u003eDownload the manufacturer safety data sheet (MSDS\/SDS)\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357817807188,"sku":"ABM134838-1","price":149.0,"currency_code":"USD","in_stock":true},{"title":"100ug","offer_id":57357817839956,"sku":"ABM134838-2","price":201.0,"currency_code":"USD","in_stock":true},{"title":"1mg","offer_id":57357817872724,"sku":"ABM134838-3","price":408.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/Primaryantibodies-CCt9H6Tc_a3a16b59-505d-4b46-bf20-2bc5aeaec5b2.svg?v=1790891154","url":"https:\/\/www.abmium.com\/products\/proteogenix-anatumomab-biosimilar-anti-tag-72-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}